Most US patients saw an increase in days of supply (DOS) for medication for chronic conditions during the pandemic, but prescription data still showed an increased likelihood of drug discontinuation, according to a study published last week in PLOS One.The researchers chose an example drug with available generics from six therapeutics classes less likely to be affected by the COVID-19 pandemic: hormonal contraception, immunosuppression, serotonin regulation, and drugs to address attention deficit hyperactivity disorder (ADHD) and psychoses.
They determined that patients had discontinued a drug if the DOS were not sufficient to cover a given month."We heard all this news about how the rules were relaxing around refills [as the pandemic